Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Operating Expenses (2018 - 2025)

Serina Therapeutics (SER) has disclosed Operating Expenses for 8 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 12.14% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.2 million through Dec 2025, up 41.21% year-over-year, with the annual reading at $24.2 million for FY2025, 41.21% up from the prior year.
  • Operating Expenses hit $6.2 million in Q4 2025 for Serina Therapeutics, down from $6.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $6.4 million in Q3 2025 to a low of $952000.0 in Q2 2023.
  • Historically, Operating Expenses has averaged $3.1 million across 5 years, with a median of $2.3 million in 2021.
  • Biggest five-year swings in Operating Expenses: tumbled 51.75% in 2023 and later skyrocketed 311.45% in 2024.
  • Year by year, Operating Expenses stood at $1.9 million in 2021, then dropped by 5.49% to $1.8 million in 2022, then soared by 59.08% to $2.8 million in 2023, then surged by 94.48% to $5.5 million in 2024, then rose by 12.14% to $6.2 million in 2025.
  • Business Quant data shows Operating Expenses for SER at $6.2 million in Q4 2025, $6.4 million in Q3 2025, and $5.7 million in Q2 2025.